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The efficacy of Triamcinolone 
acetonide in Keloid Treatment:
a systematic review and  
Meta-analysis
  
Thian-Sze Wong1, John Zeng-Hong Li1,2, Siqi Chen1, Jimmy Yu-Wai Chan1 and Wei Gao1*
1 Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, 2 Department of Otolaryngology,  
The First People’s Hospital of Foshan, Foshan, Guangdong, China
Keloid is a cutaneous dermal outgrowth resulting from uncontrolled deposition of colla-
gen and glycosaminoglycan around the wound. The uncontrolled and persistent growth 
of keloids scar will result in cosmetic disfigurement, functional impairment, and affect 
the quality of life. Triamcinolone acetonide (TAC) is traditionally employed in treating 
keloid scars. In this study, we aim to evaluate the effectiveness of TAC and compare it 
with other common therapy employed in keloid treatment. Only randomized controlled 
trial (RCT) and controlled trial were included. Inverse variance risk ratio, weighted mean 
difference, and corresponding 95% confidence intervals were calculated to evaluate the 
effect of intervention. Meta-analysis indicated that TAC treatment significantly reduced 
the size of keloid compared to untreated control. Reduction in size was statistically differ-
ent in favor of TAC compared to silicone gel sheet. Significant difference in favor of TAC 
was observed compared with verapamil in term of vascularity and scar pliability. TAC 
treatment was more effective in reducing scar thickness in comparison with cryotherapy. 
However, the current meta-analysis has several limitations. Only a limited number of trials 
with the same comparison are available. Most trials recruited a small number of patients 
and used inconsistent outcome assessment. Most trials did not provide detail informa-
tion on allocation concealment and blinding. Therefore, further evaluation in multi-center 
RCTs with consistent comparisons and outcome measurements are warrant to reach a 
consensus on the selection between TAC and different treatment modalities.
Keywords: controlled trial, keloid, meta-analysis, treatment modalities, triamcinolone acetonide
inTrODUcTiOn
Keloid is a cutaneous dermal lesion resulting from uncontrolled deposition of collagen and glycosa-
minoglycan around the wound. Elevated levels of growth factor and cytokines contribute to keloid 
formation (1–3). Transforming growth factor beta (TGF-β) family is associated with enhanced colla-
gen synthesis in keloid fibroblasts. TGF-β1 treatment stimulates the production of collagen in keloid 
fibroblasts but not in normal skin fibroblasts (1). Observation that anti-TGF-β1 antibody suppresses 
collagen synthesis of keloid fibroblasts further confirms the role of TGF-β1 (1). TGF-β2 treatment 
enhances collagen production of xenograft derived from human keloid specimens in athymic rats, 
indicating a causative role of TGF-β2 in keloid formation (2). In contrast, TGF-β2 antibody inhibits 
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collagen generation in xenograft model, suggesting that it could 
act as a potential antiscarring agent (2). Interleukin (IL)-13 
induces a more rapid increase in collagen generation in keloid 
fibroblasts compared to normal fibroblasts (3).
Keloid could grow spontaneously or grow following dermal 
trauma with poor prognosis. The uncontrolled growth of keloid 
will continue to grow without regression, and the patients will 
experience itch, pruritis, and pain. Common occurring sites 
include chest, shoulder, earlobes, and upper back (4). When the 
fibrous keloid become big, it will lead to cosmetic disfigurement, 
functional impairment, and affect the quality of life (4). Since 
keloid has notoriously high recurrence rate after surgical excision, 
non-surgical means are recommended for the primary keloid treat-
ment (5). Non-surgical means include corticosteroids injection, 
5-fluorouracil (5-FU), verapamil, silicon gel sheets, cryotherapy, 
pulsed dye laser (PDL), and radiation. Intralesional injection of 
corticosteroid triamcinolone acetonide (TAC) is one of the first-
line treatment modalities for keloid treatment (5). Corticosteroid 
is highly tolerated by the patients with a keloid. Corticosteroid 
could diminish the exuberant collagen synthesis and inhibit the 
rapid growth of keloid fibroblasts (6). In addition, corticosteroid 
could promote vasoconstriction in the keloid scar and control local 
inflammation (7). However, it is also noticed that the response 
rate of TAC treatment is highly varying with high recurrence rate 
(4, 6). TAC monotherapy may induce hypopigmentation, mixed 
pigmentation, fat atrophy, telangiectasias, necrosis, ulcerations, 
and cushingoid habitus (8). In addition, there are concern on the 
repeated use of corticosteroid at high-dose in patients with large and 
multiple keloids (4). 5-FU functions by inhibiting the synthesis of 
pyrimidine thymidine and interferes the DNA replication process 
in the rapidly dividing cells by competing with uracil (9). Verapamil 
functions by regulating the balance between fibroblasts and extra-
cellular matrix remodeling (10). Silicon gel sheets could act as an 
occlusive layer which suppresses IL-1 and IL-6 production, thus 
inhibiting fibroblast synthesis (11). Cryotherapy could destruct the 
keloid by the formation of sharp ice crystals and the induction of 
ischemic necrosis (12). PDL promotes keloid regression by photo-
thermolysis (13). The light energy emitted by PDL causes coagula-
tion necrosis of fibroblasts. PDL also suppresses proliferation and 
triggers apoptosis of fibroblasts. Radiation suppresses proliferation 
of fibroblasts, leading to a reduction in collagen generation (14).
At present, there is still no consensus of the effectiveness 
between different treatment modalities and their effectiveness 
remains controversial. The aim of the current study is to evaluate 
the efficacy of TAC-based therapy for keloid treatment. In addi-
tion, we asked whether combined treatment with TAC and other 
treatment modalities is superior to TAC alone. Finally, the effec-
tiveness of TAC-based treatment versus treatment regimes with 
the use of 5-FU, verapamil, silicon gel sheeting, or cryotherapy 
will also be performed.
MaTerials anD MeThODs
search strategy
A systematic literature retrieval was performed in different 
databases including PubMed, EMBASE, and MEDLINE using 
the search terms (((((triamcinolone) OR corticosteroids) OR 
steroids)) AND ((((((randomised controlled trials) OR controlled 
clinical trials) OR controlled clinical trial) OR randomised con-
trolled trial) OR clinical trial) OR clinical trials)) AND ((((hyper-
trophic) AND ((((scar) OR scars) OR scarred) OR scarring))) OR 
keloid). Full articles and abstract are all included. The search was 
performed in April 2016.
study selection
Two reviewers assessed the eligible trials independently. Only 
randomized controlled trial (RCT) and controlled trial (CT) 
on patients with pathological confirmed keloid were included. 
Studies that compared the regime of TAC with a non-steroid-
based treatment modality were included.
Primary and secondary Outcomes
The primary outcomes included (1) reduction in scar height, 
thickness, size, vascularity, pliability, and pigmentation and (2) 
overall scar improvement obtained from patient self-assessment 
and observer assessment. Patient self-assessment was graded 
by patients with a 5-point scale: no improvement; poor, up to 
25% improvement; fair, 26–50%; good, 51–75% improvement; 
and excellent, 76–100% improvement. Observer assessment was 
graded by the observer using a scale that was the same as patient 
self-assessment. Over 50% improvement was regarded as effective. 
The secondary outcome was improvement in erythema, pain, and 
itch. Adverse events included hypopigmentation, telangiectasia, 
and skin atrophy.
Data extraction
Two reviewers extracted data independently. Study character-
istics (author, year of publication, country, number of patients, 
intervention and control, follow-up period, primary and 
secondary outcomes) and participant characteristics (age and 
sex) were summarized. The numbers of patients with >50% 
improvement, >50% reduction in size, or any specific adverse 
event were extracted from both arms of intervention. The values 
of Vancouver Scar Scale including scar pigmentation, vascularity, 
pliability, and height were extracted from both groups. The values 
of scar thickness before and after intervention were also extracted.
evaluation of risk of Bias
The risk of bias was evaluated according to Cochrane handbook 
and analyzed by Review Manager 5.3. The parameters included 
random sequence generation, allocation concealment, blinding, 
incomplete outcome data, and selective reporting.
statistical analysis
For dichotomous variables, inverse variance risk ratio (RR) and 
corresponding 95% confidence intervals (CI) were calculated to 
evaluate the effect of intervention. For continuous data compari-
sons, weighted mean difference (WMD) and 95% CI were calcu-
lated. Heterogeneity between studies was assessed using p value of 
I2 statistics. p value of I2 statistics smaller than 0.1 was classified as 
indication of substantial heterogeneity. Where heterogeneity was 
observed, random effects model was used. In contrast, fixed effect 
FigUre 1 | schematic representation of the search strategy and risk of bias summary of selected studies. (a) Flow chart showing the selection process 
of the studies in the meta-analysis. (B) review authors’ judgments about each risk of bias item for each included study. +, low risk; −, high risk; ?, unclear risk.
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model was adopted. For TAC treatment, different dosages of TAC 
were used. A subgroup analysis was performed according to the 
dosage of TAC. All the analysis was carried out using STATA ver-
sion 12.0 (StataCorp). Unless otherwise specified, p value below 
0.05 was denoted as statistical significance.
resUlTs
Paper selection and study characteristics
A total of 113 studies were identified by searching Pubmed, 
EMBASE, and Medline. After excluding 101 irrelevant studies, 
12 studies were selected for further evaluation and all the studies 
were available in full paper (Figure 1A). Four studies were further 
excluded due to duplicate publication or no data on defined pri-
mary and secondary outcomes available. The study of Darougheh 
et al. (15) has duplicate data with Asilian et al. (16); therefore, it 
was excluded for meta-analysis. No data on reduction in scar size 
or overall scar improvement could be extracted from the studies 
of Layton et al. (17), Sproat et al. (18), and Kelemen et al. (19). 
Finally, eight studies were included in this meta-analysis (11, 16, 
20–25). The characteristics of these eight studies were shown in 
Table 1.
risk of Bias in included studies
The risk of bias of eight studies included in this meta-analysis 
was summarized in Figure 1B. Since the studies of Yosipovitch 
et al. (20) and Tan et al. (11) were not RCT, they were judged as 
high risk for random sequence generation. Four studies (22–25) 
provided the method used to generate random sequence and 
were judged to be at low risk of random sequence generation. Two 
studies (16, 21) did not report the method of generating random 
sequence and we judged them at unclear risk. Allocation conceal-
ment was not reported in all of the eight studies (11, 16, 20–25), 
and we judged all trials as unclear for allocation concealment. 
Two single-blinded trials (16, 24) were judged as high risk for 
blinding of participants and personnel. Complete information on 
the blinding processes was not shown by the left six studies (11, 
TaBle 1 | characteristics of the studies selected in this meta-analysis.
author Year country Type of 
assessment
age 
(years)
gender 
(male/
female)
no. of 
patients 
(arm 1)
no. of patients 
(arm 2)
Follow-up Treatment 
in arm 1
Treatment in 
arm 2
Triamcinolone acetonide (Tac) versus control
Tan et al. (11) 2009 Singapore Reduction in 
size
19–40 18/2 20 (TAC) 20 (Control) 12 weeks TAC 40 mg/
ml
No treatment
Tac versus silicone gel sheet
Tan et al (11) 2009 Singapore Reduction in 
size
19–40 18/2 20 (TAC) 20  
(Silicone gel sheet)
12 weeks TAC 40 mg/
ml
Silicone gel sheet
Tac versus 5-fluorouracil (5-FU)
Sadeghinia and 
Sadeghinia (22)
2012 Iran Patient 
self-assessment 
NA NA 20 (TAC) 20 (5-FU) 44 weeks TAC 40 mg/
ml
5-FU 50 mg/ml
Manuskiatti and 
Fitzpatrick (21)
2002 Thailand Patient 
self-assessment
25–74 4/6 10 (TAC) 10 (5-FU) 32 weeks TAC 20 mg/
ml
5-FU 50 mg/ml
Tac versus Tac + 5-FU
Asilian et al. (16) 2006 Iran Patient 
self-assessment 
5–70 15/25 20 (TAC) 20 (TAC + 5-FU) 12 weeks TAC 10 mg/
ml
TAC 4 mg/ml + 5-FU 
45 mg/ml
Khan et al. (23) 2014 Pakistan Observer 
assessment
NA 65/85 75 (TAC) 75 (TAC + 5-FU) 12 weeks TAC 10 mg/
ml
TAC 4 mg/ml + 5-FU 
45 mg/ml
Manuskiatti and 
Fitzpatrick (21)
2002 Thailand Patient 
self-assessment
25–74 4/6 10 (TAC) 10 (TAC + 5-FU) 32 weeks TAC 20 mg/
ml
TAC 1 mg/ml + 5-FU 
45 mg/ml
Tac versus verapamil
Margaret Shanthi 
et al. (24)
2008 India Vancouver scar 
scale
NA NA 27 (TAC) 27 (Verapamil) 24 weeks TAC 40 mg/
ml 
Verapamil 2.5 mg/ml
Ahuja and  
Chatterjee (25)
2014 India Vancouver scar 
scale
15–60 NA 22 (TAC) 26 (Verapamil) 24 weeks TAC 40 mg/
ml
Verapamil 2.5 mg/ml
Tac versus cryotherapy
Yosipovitch  
et al. (20)
2001 Singapore Scar thickness 17–50 NA 10 (TAC) 8 (Cryotherapy) 4 weeks TAC 40 mg/
ml
Cryotherapy
Tac versus Tac + cryotherapy
Yosipovitch  
et al. (20)
2001 Singapore Scar thickness 17–50 NA 10 (TAC) 10 
(TAC + cryotherapy)
4 weeks TAC 40 mg/
ml
TAC 40 mg/ml +  
cryotherapy
NA, not available.
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20–23, 25) and we judged them at unclear risk for performance 
bias. Two studies (16, 25) employed blinded observer to assess 
outcomes and were judged at low risk of detection bias. The left 
six trials (11, 20–24) were judged as unclear risk due to no report 
on blinding of outcome assessment. Four trials (11, 16, 20, 24) 
were judged at high risk for incomplete outcome data because the 
numbers lost to follow up were high and no reasons were given 
for the losses. No reporting bias or other bias was observed in 
all eight studies (11, 16, 20–25). In summary, most studies have 
no detail information on allocation concealment, blinding of 
participants and personnel, and blinding of outcome assessment.
Tac versus control
Tan et al. (11) evaluated the efficacy of TAC in keloid treatment. 
A total of 20 patients with multiple keloids were recruited and 
treated by TAC for 12  weeks. Seventeen patients in both TAC 
group and control group completed the 12-week treatment. A 
significant difference was observed in >50% reduction in size 
(RR: 33.00, 95% CI: 2.14–509.33) and improvement in erythema 
(RR: 21.00, 95% CI: 1.33–332.06), favoring TAC in comparison 
with control. In terms of improvement in pain and itch, there 
was no statistically significant difference. These results indicated 
that TAC treatment significantly reduced the size and improved 
appearance of keloid.
Tac versus silicone gel sheet
Tan et al. (11) compared the effectiveness of TAC with silicone gel 
sheet in keloid treatment. Seventeen patients in both TAC group 
and silicone gel sheet group completed the 12-week treatment. 
The >50% reduction in size (RR: 8.00, 95% CI: 2.16–29.57) and 
improvement in erythema (RR: 10.00, 95% CI: 1.43–69.77) were 
statistically different in favor of TAC compared to silicone gel 
sheet. For improvement in pain and itch, no apparent difference 
was observed. TAC treatment not only resulted in a decrease in 
size but also normalized symptoms of keloid in comparison with 
silicone gel sheet.
Tac versus 5-FU
The efficiency of TAC was compared with 5-FU in two trials (21, 
22). In the study of Manuskiatti and Fitzpatrick (21), 10 patients 
including 6 women and 4 men with age ranging from 25 to 
74 were treated by TAC or 5-FU. Over 50% improvement was 
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observed in 10 out of 10 patients in both TAC arm and 5-FU 
arm. The RR was 1 with the standard error of the log relative risk 
to be 0 and 95% CI was 1 to 1. In data synthesis, this study was 
excluded by STATA. Sadeghinia and Sadeghinia (22) compared 
the effects of TAC and 5-FU using patient self-assessment. Forty 
patients were randomized into TAC group (20 patients) or 5-FU 
group (20 patients). The ratio of patients with >50% overall 
improvement was compared. A significant improvement in favor 
of 5-fluorouracil compared to those treated with TAC (RR: 2.12, 
95% CI: 1.20–3.75). The study of Sadeghinia and Sadeghinia (22) 
showed that no side effect was detected in both TAC and 5-FU 
group. In contrast, Manuskiatti and Fitzpatrick (21) reported that 
skin atrophy, telangiectasia, and hypopigmentation were noted 
in 50% segments of TAC group but not in 5-FU group. However, 
the difference in complications between TAC and 5-FU groups 
was not statistically significant (RR: 11.0, 95% CI: 0.69–175.86).
Tac versus Tac with 5-FU
Three trials compared the effects of TAC alone with the combi-
nation of TAC and 5-FU (16, 21, 23). There are two outcomes 
including patient self-assessment and observer assessment. 
Over 50% improvement was regarded as effective. There was no 
significant difference between the two groups (RR: 1.18, 95% CI: 
0.83–1.69; Figure 2A). For TAC treatment, there are two different 
regimes: (A) TAC 10 mg/ml, once weekly, eight sessions; and (B) 
TAC 20 mg/ml, once every 4 weeks, six sessions. For the com-
bination treatment using TAC and 5-FU, TAC dosage reduced 
to 1–4 mg/ml together with 45 mg/ml 5-FU. Except Manuskiatti 
and Fitzpatrick (21) (regime B, 20 mg/ml), all other studies used 
the same treatment regime (regime A, 10  mg/ml). When we 
performed subgroup analysis based on the treatment regime, a 
statistically significant difference in favor of TAC with 5-FU was 
only observed in the studies using 10  mg/ml TAC (RR: 1.27, 
95% CI: 1.06–1.52; Figure 2B) but not in the study using 20 mg/
ml TAC (RR: 0.90, 95% CI: 0.69–1.18; Figure 2B). In terms of 
complications, patients in TAC group have a higher risk to experi-
ence skin atrophy and telangiectasia compared with combination 
treatment using TAC and 5-FU (RR: 3.65, 95% CI: 1.65–8.08; 
Figure 2C). TAC plus 5-FU showed advantages over TAC alone 
only when a low dose of TAC was used in TAC monotherapy.
Tac versus Verapamil
Two trials (24, 25) compared the use of TAC with verapamil. 
Forty patients (48 scars) were divided into TAC group (22 
scars) and verapamil group (26 scars) in the study of Ahuja and 
Chatterjee (25). In the trial of Margaret Shanthi et  al. (24), 54 
patients were allocated to TAC arm (27 patients) and verapamil 
arm (27 patients). In both trials, Vancouver Scar Scale including 
scar pigmentation, vascularity, pliability, and height was used 
to measure the treatment effects. For scar pigmentation, no 
statistical difference between TAC and verapamil was observed 
at 3 weeks (WMD: −0.10, 95% CI: −0.32–0.12; Figure 3A); when 
vascularity was used as outcome, there was a statistically signifi-
cant difference in favor of TAC compared to verapamil at 3 weeks 
(WMD: −0.22, 95% CI: −0.44 to −0.01; Figure  3B); in terms 
of scar pliability, significant improvement in favor of TAC was 
observed after 3 weeks (WMD: −0.39, 95% CI: −0.60 to −0.18; 
Figure 3C); for scar height, no statistical difference between TAC 
and verapamil was noticed (WMD: −0.05, 95% CI: −0.24–0.14; 
Figure 3D). Although Margaret Shanthi et al. (24) reported that 
complications were seen in both groups, no data were presented. 
In the trial of Ahuja and Chatterjee (25), the difference in 
complications including skin atrophy and telangiectasia was not 
statistically significant between TAC and verapamil groups (RR: 
15.26, 95% CI: 0.91–256.58). TAC treatment improved the symp-
toms of keloid but not reduced the height of keloid compared to 
verapamil.
Tac versus cryotherapy
The effectiveness of TAC was compared with cryotherapy by 
Yosipovitch et al. (20). Fourteen patients with at least two keloids 
aged between 17 and 50 years were enrolled in this study. The 
WMD in scar thickness was statistically different in favor to TAC 
(WMD: −3.35, 95% CI: −4.95 to −1.75).
Tac versus Tac Plus cryotherapy
Yosipovitch et al. (20) compared the efficacy between TAC and 
TAC plus Cryotherapy. The WMD in scar thickness was statisti-
cally different in favor to TAC plus cryotherapy (WMD: −4.60, 
95% CI: −7.54 to −1.66).
DiscUssiOn
Keloid is an excessive scar with high tendency to extend beyond 
the initial wound margin and persistent long without spontane-
ous regression (6). Surgical manipulation is not the best option for 
keloid management as the recurrence rate is high (5). Alternative 
therapies using corticosteroids injection, chemotherapeutic 
agents, verapamil, silicon gel sheets, and cryotherapy become 
important especially in case where patients presented with high 
recurrence rate after surgery (4). Selection between different 
treatment modalities is usually experience based and the varying 
success rates were obtained. Khansa et al. performed a literature 
review to provide evidence-based evaluation on the effective-
ness of different treatment methods for keloid (26). Treatment 
modalities including silicone gel, PDL, TAC, and 5-FU showed 
high efficacy in improving keloid. In contrast, onion extract and 
fat grafting exhibited low efficiency (26). In this study, we further 
compared the effectiveness of TAC with different treatment 
regimes.
Although intralesional injection of TAC is one of the first-line 
treatments for keloid, prospective CTs comparing its efficacy 
with different treatment modalities remained few and presented 
with different outcomes (27). Results from current meta-analysis 
showed that TAC treatment resulted in marked reduction in the 
size of keloid in comparison with untreated control. TAC was 
more effective in improving scar than silicone gel sheet, vera-
pamil and cryotherapy. In addition, 5-FU showed a significant 
improvement of keloid in comparison with TAC. Although TAC 
treatment could lead to complications including skin atrophy 
and telangiectasia, the difference was not statistically significant 
compared to 5-FU or verapamil.
Bijlard et  al. (28) performed an up-to-date review on the 
RCTs, prospective clinical trials, and case series involving keloid 
FigUre 2 | Triamcinolone acetonide (Tac) versus Tac with 5-FU in keloid treatment. (a) Forest plot representing difference in over 50% improvement 
between TAC and TAC with 5-FU. (B) Effects of treatment regime on improvement. (c) Complications of TAC and TAC with 5-FU.
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treatment using intralesional 5-FU alone or in combination. In 
general, keloid treated with 5-FU showed good outcome with 
reduced pain and pruritis. However, patients may experience 
adverse event accompanied with the used of chemotherapeutic 
drug such as pain at injection site, ulceration, and burning 
sensation (28). It should also be noted that the use of 5-FU in 
keloid treatment has multiple limitations. Although the use of 
5-FU at high-dose without the presentation of hematological 
complication is reported, the use should be cautious in cases of 
pregnancy, lactation, intercurrent infection, and bone marrow 
depression (29).
The use of TAC together with the chemotherapeutic drug 5-FU 
is increasing. In the study of Shah et al., 5-FU in conjunction with 
TAC displayed the highest efficiency in improving the symptoms 
of scars and decreasing recurrence (30). Our subgroup analysis 
revealed that TAC in combination with 5-FU was more effective 
than TAC alone only when TAC was used at a low concentra-
tion (10  mg/ml). The combination treatment was not superior 
to TAC alone when 20 mg/ml TAC was employed. In order to 
achieve keloid resolution, TAC at high concentration (40 mg/ml) 
is recommended for TAC monotherapy (31). Thus, we could not 
conclude that TAC plus 5-FU offers a better treatment outcome 
in comparison with TAC. In addition, the effects of TAC in the 
combination treatment is difficult to assess as all authors reduced 
the TAC concentration (from 10–20 mg/ml to 1–4 mg/ml) when 
used in combination with 5-FU. Usually, the use of TAC in the 
combination treatment is not for therapeutic intent. It is used 
for the potential inflammation events accompanied with the 
5-FU treatment (29). However, TAC plus 5-FU exhibited lower 
complications compared with TAC alone.
Verapamil is a calcium antagonist which could induce 
procollagenase production leading to the reduction in collagen 
production in scar fibroblasts (7). The calcium channel blocker 
could induce a phenotypic change in fibroblast from bipolar 
shape to spheroidal shape by depolymerizating the actin filament 
(32). Verapamil triggers extracellular matrix remodeling by 
preventing tritiated proline incorporation (33). The use of vera-
pamil in patients with burn scars is considered to be safe and 
cost-effective. Lawrence (34) was the first group who employed 
the use of verapamil in earlobe keloid treatment. They showed 
FigUre 3 | comparison of triamcinolone acetonide (Tac) with verapamil in the treatment of keloid. Forest plot showing differences in pooled scar 
pigmentation (a), vascularity (B), pliability (c), and height (D) between TAC and verapamil treatment.
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that 52% keloid patients were cured when intralesional verapamil 
(2.5 mg/ml) was administered at 7–14 day after keloid removal. 
Verapamil was administered at 1-month interval where feasible. 
In comparison with TAC, there was a significant improvement 
in favor of TAC if we used scar vascularity (at 3  weeks) and 
scar pliability (at 3 weeks) as outcomes. In contrast, when scar 
pigmentation and height were used, no statistical significant dif-
ference was observed. These results indicated that TAC reduced 
the scar vascularity and pliability faster than verapamil.
TAC is widely used as first-line therapy in treating keloid by 
practitioners. However, its functional mechanism is less clear in 
comparison with other treatment modalities examined in the cur-
rent study. Given that TAC treatment will lead to substantial side 
effects, selection between TAC and other treatment options should 
be evidence based and the discernible benefits shall be clarified. 
Observation that TAC treatment is more effective in improving 
keloid in comparison with silicone gel sheet, verapamil, and cryo-
therapy promotes us to recommend TAC for keloid treatment. In 
light of that TAC in combination with 5-FU has reduced complica-
tions in comparison with TAC monotherapy, TAC in conjunction 
with 5-FU should be recommended for keloid treatment.
There are several limitations in our systematic reviews. We 
found that there are no sufficient research trials comparing 
TAC and other treatment options. The trials performed using 
inconsistent outcome assessment with varying follow-up period. 
No data on recurrence are available in most trials. Given that 
keloid is a disease with high recurrence rate, comparison between 
TAC and other treatment modalities in preventing keloid recur-
rence shall be performed. For the dosage of TAC injection, most 
study used TAC at 40 mg/ml. However, there are not much data 
on the injection volume and keloid size. In addition, most trials 
only recruit a small number of patients with keloid at different 
anatomical locations. For the dermatological examination, 
Vancouver Scar Scale (evaluation of vascularity, pigmentation, 
pliability, and height), observer assessment, and self-assessment 
were used at different follow-up duration with no information on 
the blinded assessment. Further evaluation in multi-center RCTs 
with consistent objective, repeatable outcome, and recurrence 
measurement are warrant to reach a consensus on the selection 
between TAC and different treatment modalities.
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